<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812864</url>
  </required_header>
  <id_info>
    <org_study_id>I07028</org_study_id>
    <secondary_id>N° EudraCT : 2008-001195-7</secondary_id>
    <nct_id>NCT00812864</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥ 75 Years)</brief_title>
  <acronym>capagec</acronym>
  <official_title>Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥75 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine blood concentration evolution of capecitabine and its
      active metabolites, in elderly patient 75 years and more.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood samples will be taken before 1rst course of chemotherapy of capécitabine for colorectal
      or breast metastatic cancer.

      Pharmacokinetic will be realizes at several times (H0,5, H1, H1,5, H2, H4, H6, H8) and
      repeated at D14 of the 2d cycle
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean value and dispersion of the main plasmatics pharmacokinetics parameters of capécitabine, 5'DFUR, 5-FU and FBAL.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects evaluation after every course of chemotherapy according to NCI criteria during 6 courses maximum.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response comparing lesions' targets according to RECIST criteria, at course n°3 and n°6.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Pharmacokinetic of its metabolites.
Capecitabine, 1250 mg/m2 twice a day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elderly patients 75 years old or more

          -  Life expectancy of greater then or equal to 6 months

          -  Histologically proven metastatic breast or colorectal cancer, requiring a chemotherapy
             by capecitabine according to the habitual schema

          -  Metastatic situation whatever treatment line

          -  Previous hormonotherapy for breast cancer, prior chemotherapy (without capecitabine)
             in adjuvant and/or metastatic indication (colorectal or breast cancer), or
             radiotherapy (colorectal or breast cancer) are allowed

          -  One or more measurable target lesion (RECIST criteria)

          -  ADL&gt;4 (geriatric scales)

          -  GSD&lt;12 (geriatric scales)

          -  Laboratory values :

               -  creatinine clearance (CrCl) &gt;=30 mL/min according to Cockcroft formula

               -  Adequate bone marrow function (neutrophils count &gt; 1.5 x 10^9/L, platelets &gt; 100
                  x 10^9/L, hemoglobin [Hb] &gt; 10g/dl)

               -  Adequate hepatic function: total bilirubin &lt; 1,5 x upper normal limit, aspartate
                  aminotransferase (ASAT) and alanine aminotransferase (ALAT) &lt; 2,5x upper normal
                  limits (in case of liver metastases &lt; 5 x upper normal limits)

               -  Alcalin phosphatases &lt;=2,5x ULN (&lt;=5 x ULN if liver metastases present).

          -  Subjects must be willing to be followed during the course of treatment/observation and
             follow-up.

          -  Signed written informed consent before first course of chemotheray

        Exclusion Criteria:

          -  Age &lt; 75 years

          -  known brain metastases

          -  Concomitant oncologic treatment ongoing

          -  History of severe or unscheduled reaction to fluoropyrimidine treatment

          -  Prior unanticipated severe reaction to capecitabine or metabolites and to
             fluoropyrimidine therapy

          -  Patient with leucopenia

          -  sorivudine or chemical analogues treatment like brivudine

          -  Physiological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.

          -  Concomitant severe affections wich lead life expectancy inferior to 3 monthes

          -  Uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure,
             coronarian spasmes

          -  No possible oral administration

          -  known DPD deficiency

          -  Treatment with experimental therapy ongoing or within four weeks before inclusion.

          -  Other cancers within the last five years, with the exception of adequately treated
             cone-biopsied in situ carcinoma of the uterin cervix or basal or squamous cell
             carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole TUBIANA-MATHIEU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Limoges, medical oncology department ,02 avenue Martin Luther King 87042 Limoges cedex France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges Cedex</city>
        <state>Province</state>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Capecitabine</keyword>
  <keyword>pharmacocinetics</keyword>
  <keyword>Breast metastatic cancer</keyword>
  <keyword>colorectal metastatic cancer</keyword>
  <keyword>Elderly patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

